Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors.
Digestive System Surgical Procedures
/ methods
Female
Follow-Up Studies
Humans
Intestinal Neoplasms
/ mortality
Male
Middle Aged
Neoplasm Metastasis
Neoplasm Staging
Neuroendocrine Tumors
/ mortality
Pancreatic Neoplasms
/ mortality
Prognosis
Retrospective Studies
Stomach Neoplasms
/ mortality
Survival Rate
/ trends
Time Factors
United States
/ epidemiology
Neuroendocrine tumors
carcinoid tumors
colorectal neoplasms
gastrointestinal neoplasms
pancreatic neoplasms
Journal
Surgery
ISSN: 1532-7361
Titre abrégé: Surgery
Pays: United States
ID NLM: 0417347
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
14
06
2018
revised:
11
08
2018
accepted:
05
09
2018
pubmed:
28
10
2018
medline:
18
12
2019
entrez:
28
10
2018
Statut:
ppublish
Résumé
Patients with gastroenteropancreatic neuroendocrine tumors often present with stage IV disease. Primary tumor resection in these patients remains controversial. Herein, we studied the impact of primary tumor removal, identified variables associated with prolonged survival for each neuroendocrine tumor subtype, and determined factors that influence surgeons to perform primary tumor resection. Patients with metastatic gastroenteropancreatic neuroendocrine tumors diagnosed from 2004 to 2014 were identified from the National Cancer Database. Nested Cox proportional hazards and logistic regression models were used to assess variables associated with survival and primary resection. A total of 14,510 patients met inclusion criteria. On multivariable analysis, resection of the primary tumor and grade 1 or 2 tumors was associated with prolonged survival in all subtypes (P < .001). Organ-specific variables associated with prolonged survival in patients undergoing primary tumor resection included the following: low grade for all organs; young age for pancreatic, small intestinal, colonic, and rectal neuroendocrine tumor; tumor size for colonic and rectal neuroendocrine tumor; and tumor location for colonic neuroendocrine tumor. Low tumor grade was found to be significantly associated with removal of the primary tumor across all organs. This study is the first suggesting that primary tumor resection is associated with prolonged survival for all gastro-entero-pancreatic NETs. Additional variables related to survival for each NET subtype were identified and might help select patients who benefit from primary tumor removal.
Sections du résumé
BACKGROUND
Patients with gastroenteropancreatic neuroendocrine tumors often present with stage IV disease. Primary tumor resection in these patients remains controversial. Herein, we studied the impact of primary tumor removal, identified variables associated with prolonged survival for each neuroendocrine tumor subtype, and determined factors that influence surgeons to perform primary tumor resection.
METHODS
Patients with metastatic gastroenteropancreatic neuroendocrine tumors diagnosed from 2004 to 2014 were identified from the National Cancer Database. Nested Cox proportional hazards and logistic regression models were used to assess variables associated with survival and primary resection.
RESULTS
A total of 14,510 patients met inclusion criteria. On multivariable analysis, resection of the primary tumor and grade 1 or 2 tumors was associated with prolonged survival in all subtypes (P < .001). Organ-specific variables associated with prolonged survival in patients undergoing primary tumor resection included the following: low grade for all organs; young age for pancreatic, small intestinal, colonic, and rectal neuroendocrine tumor; tumor size for colonic and rectal neuroendocrine tumor; and tumor location for colonic neuroendocrine tumor. Low tumor grade was found to be significantly associated with removal of the primary tumor across all organs.
CONCLUSION
This study is the first suggesting that primary tumor resection is associated with prolonged survival for all gastro-entero-pancreatic NETs. Additional variables related to survival for each NET subtype were identified and might help select patients who benefit from primary tumor removal.
Identifiants
pubmed: 30366604
pii: S0039-6060(18)30650-0
doi: 10.1016/j.surg.2018.09.006
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
644-651Informations de copyright
Copyright © 2018 Elsevier Inc. All rights reserved.